Form 13-F position report

INNOVATE BIOPHARMACEUTICLS

Reported by GEODE CAPITAL MANAGEMENT LLC

NMTRQ CUSIP 45782F105 Manager CIK 0001214717

Reported 0 shares, down 113,968 (100.0%) from the prior quarter.

Reported value -100.0%; share count -100.0% vs. the prior quarter.

Reduced
% of reported 13F value 0 This manager · Q2 2020
Shares 0 Quarter-end amount reported
Reported value $0 Fair value at quarter end
Consecutive quarters held 9 Through Q2 2020

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value

Quarterly position history

How this manager's reported quarter-end position changed over time.

0 quarters
Quarterly reported position history for INNOVATE BIOPHARMACEUTICLS held by GEODE CAPITAL MANAGEMENT LLC.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
This position's reported history falls outside the five-year preview window. A free account unlocks it. Unlock full history

Who else reported the position

20 managers reported INNOVATE BIOPHARMACEUTICLS for Q2 2020.

Managers reporting INNOVATE BIOPHARMACEUTICLS in Q2 2020.
Manager Activity Shares Change % of reported 13F Reported value Tenure
CITADEL ADVISORS LLC Reduced 0 -51,062 0 $0 2 qtrs
GEODE CAPITAL MANAGEMENT LLC This report Reduced 0 -113,968 0 $0 9 qtrs
RENAISSANCE TECHNOLOGIES LLC Reduced 0 -225,399 0 $0 3 qtrs
Summit X LLC Reduced 0 -34,000 0 $0 4 qtrs
VICTORY CAPITAL MANAGEMENT INC Reduced 0 -5,655 0 $0 4 qtrs
BREWIN DOLPHIN Ltd Reduced 0 -25,000 0 $0 5 qtrs
DEUTSCHE BANK AG Reduced 0 -3,173 0 $0 10 qtrs
BlackRock Inc Reduced 0 -355,175 0 $0 10 qtrs
WELLS FARGO & COMPANY MN Reduced 0 -146 0 $0 9 qtrs
VANGUARD GROUP INC Reduced 0 -721,046 0 $0 9 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
June 30, 2020
Filed
August 13, 2020
Filing type
13F-HR
Position type
COM PAR

Voting authority reported

No voting-authority amounts were reported for this position. Voting authority is not required for reported call options.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.